Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Barinthus Biotherapeutics PLC BRNS

Healthcare Biotechnology
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These... see more

Recent & Breaking News (NDAQ:BRNS)

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

GlobeNewswire 11 days ago

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

GlobeNewswire November 25, 2024

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

GlobeNewswire November 15, 2024

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

GlobeNewswire November 6, 2024

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 - The Liver Meeting® and Attendance at November Conferences

GlobeNewswire October 31, 2024

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

GlobeNewswire October 1, 2024

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

GlobeNewswire September 24, 2024

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

GlobeNewswire August 8, 2024

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

GlobeNewswire August 1, 2024

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

GlobeNewswire June 12, 2024

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

GlobeNewswire June 6, 2024

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

GlobeNewswire May 22, 2024

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

GlobeNewswire May 13, 2024

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

GlobeNewswire May 1, 2024

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

GlobeNewswire April 18, 2024

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

GlobeNewswire March 20, 2024

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

GlobeNewswire January 5, 2024

New partnership aims to advance vaccine against MERS coronavirus

GlobeNewswire December 21, 2023

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

GlobeNewswire November 9, 2023

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

GlobeNewswire November 9, 2023